# US 2021/0275463 A1 · Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275463 A1
- Document ID: US20210275463A1
- Status: Published application
- Kind: A1
- Application number: 17/193,058
- Filed: 2021-03-05
- Published: 2021-09-09
- Earliest claimed: 2016-09-13
- Assignees: Tiziana Life Sciences PLC
- Applicants: Tiziana Life Sciences PLC
- Inventors: Kunwar SHAILUBHAI
- Web page: https://patentgrep.com/patent/US20210275463A1

## CPC

- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure provides compositions comprising dactinomycin, formulated for delivery by nanoparticle, and methods for treating a myelodysplastic syndrome (MDS) or cancer, for example, NPM1-mutated acute myeloid leukemia (AML), by administration of the compositions of the disclosure.

## Claims

### Claim 1

A composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles comprising
PLA-mPEG, wherein the nanoparticles have an average size of about 100 nm to about 200 nm.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the PLA-mPEG comprises about 5% mPEG to about 50% mPEG by weight.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the molecular weight of the PLA-mPEG is about 25,000 Da to about 35,000 Da.

### Claim at position 4

-8. (canceled)

### Claim 9

A composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles comprising
PLGA-mPEG, wherein the nanoparticles have an average size of about 100 nm to about 200 nm.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the PLGA has a lactic acid:glycolic acid molar ratio of about 40:60 to about 60:40.

### Claim 11

(canceled)

### Claim 12 (depends on 9)

The composition of claim 9, wherein the PLGA-mPEG comprises about 5% mPEG to about 50% mPEG by weight.

### Claim 13 (depends on 9)

The composition of claim 9, wherein the molecular weight of the PLGA-mPEG is about 17,000 Da to about 27,000 Da.

### Claim at position 10

-20. (canceled)

### Claim 21

A composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles comprising
poly(lactic acid) (PLA), wherein the nanoparticles have an average size of about 100 nm to about 200 nm.

### Claim 22 (depends on 21)

The composition of claim 21, wherein the PLA is ester terminated.

### Claim 23 (depends on 22)

The composition of claim 22, wherein the molecular weight of the PLA is between about 10,000 Da to about 18,000 Da.

### Claim 24 (depends on 21)

The composition of claim 21, wherein the PLA is acid terminated.

### Claim 25 (depends on 24)

The composition of claim 24, wherein the molecular weight of the PLA is about 18,000 Da to about 24,000 Da.

### Claim at position 16

-37. (canceled)

### Claim 38 (depends on 1)

A method for treating a myelodysplastic syndrome (MDS) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the composition of claim 1.

### Claim 39 (depends on 1)

A method for treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the composition of claim 1, wherein the cancer is acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), colorectal cancer, neuroendocrine cancer, esophageal cancer, or gastrointestinal stromal tumor (GIST).

### Claim at position 19

-51. (canceled)

### Claim 52 (depends on 1)

A process for preparing the composition of claim 1, comprising:
(i) Adding a solution of dactinomycin in organic solvent to a solution of the polymer in organic solvent until the polymer:API ratio is 10:1 ratio (weight/weight);
(ii) vortexing the solution from (i) until homogeneous
(iii) adding the solution from (ii) dropwise into a water phase containing 2% (w/w) polyvinyl alcohol, with a molecular weight of 9,000-10,000 Da, 80% hydrolyzed, while said water phase was on high vortex, until the ratio of the solution from (ii) to the water phase was about 1:7, by volume, forming a nanoparticle emulsion;
(iv) vortexing the emulsion from (iii);
(v) sonicating the emulsion from (iv) for several minutes at 0° C.; followed by pouring the emulsion into a stirring water phase solution containing 2% (w/w) polyvinyl alcohol, and continue stirring until organic solvent evaporates and, optionally:
(vi) purifying the composition by centrifugation for about 30 minutes at 14,000× rpm;
(vii) discarding the supernatant from (vi), followed by washing the resulting nanoparticles with ddH2O, centrifugation for 30 minutes at 14,000× rpm;
(viii) resuspending the product from (viii) in ddH2O followed by centrifugation for 5 minutes at 3500× rpm; and
(ix) collecting the supernatant from (viii) and then concentrating by an Amicon® Ultra Centrifugal filter (50 kD cut-off), followed by centrifugation for 10 minutes at 14,000× rpm to remove free dactinomycin.

### Claim 53 (depends on 52)

The process of claim 52, wherein the amount of free dactinomycin in the composition is less than 5%, 4%, 3%, 2%, or 1% by weight of the amount of dactinomycin encapsulated in nanoparticles.

### Claim 54 (depends on 9)

A method for treating a myelodysplastic syndrome (MDS) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the composition of claim 9.

### Claim 55 (depends on 9)

A method for treating acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), colorectal cancer, neuroendocrine cancer, esophageal cancer, or gastrointestinal stromal tumor (GIST) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the composition of claim 9.

### Claim 56 (depends on 21)

A method for treating a myelodysplastic syndrome (MDS) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the composition of claim 21.

### Claim 57 (depends on 21)

A method for treating acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), colorectal cancer, neuroendocrine cancer, esophageal cancer, or gastrointestinal stromal tumor (GIST) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the composition of claim 21.
